Despite drug launch streak, Lilly posts rare sales decline as Alimta succumbs to generics

Even as Eli Lilly puts much of its energy behind a suite of new drug launches, an older cancer medicine that just tumbled off the patent cliff is proving to be a big drag on the company's financial performance.